Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction

Open access
Martens, Pieter, Beliën, Hanne, Dupont, Matthias, Vandervoort, Pieter, Mullens, Wilfried · 2018 · Cardiovascular Therapeutics

Abstract

Summary: Background: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. Methods: We performed a single‐center, prospective assessor‐blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]‐class II‐IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin‐Angiotensin‐System‐Blocker [RAS‐blocker]). Doses of sacubitril/valsartan were optimized to individual tolerance. Echocardiographic images were assessed offline by 2 investigators blinded to both the clinical data and timing of echocardiograms. Results: One‐hundred‐twenty‐five HFrEF patients (66 ± 10 years) were prospectively included. The amount of RAS‐blocker before and after switch to sacubitril/valsartan was similar(P = .290), indicating individual optimal dosing of sacubitril/valsartan. Over a median(IQR) follow‐up of 118(77‐160) days after initiation of sacubitril/valsartan, LVEF improved (29.6 ± 6% vs 34.8 ± 6%; P < .001) and Left ventricular end‐systolic (LVESV) and end‐diastolic volume (LVEDV) decreased (LVESV; 147 ± 57 mL vs 129 ± 55 mL; P < .001 and LVEDV; 206 ± 71 mL vs197 ± 72 mL; P = .027). Volumetric remodeling was associated with a reduction in the degree of mitral regurgitation (1.59 ± 1.0 vs 1.11 ± 0.8; P < .001; [scale from 0‐4]). Metrics of diastolic function improved; including a drop in the E/A‐wave ratio (1.75 ± 1.13 vs 1.38 ± 0.88; P = .002) and diastolic filling time (% of cycle length) prolonged (48 ± 9% vs 52 ± 1%; P = .005). The percent of patients with a restrictive mitral filling pattern dropped from 47% to 23% (P = .004). A dose‐dependent effect was noted for changes in LVEF (P < .001) and LVESV (P = .031), with higher doses of sacubitril/valsartan leading to more reverse remodeling. Conclusion: Switching therapy in eligible HFrEF patients from a RAS‐blocker to sacubitril/valsartan induces beneficial reverse remodeling of both metrics of systolic as diastolic function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1755-5922.12435

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 179

Metadata

Authors
Martens, P., Beliën, H., Dupont, M., Vandervoort, P., & Mullens, W.
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2018-06-07
Volume
36
Issue
4
Pages
e12435-e12435
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W2805015756
Cited by
179
References
4
FWCI
14.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. https://app.cochat.ai/papers/10.1111/1755-5922.12435
The paper
Martens, P., Beliën, H., Dupont, M., Vandervoort, P., & Mullens, W. (2018). The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovascular Therapeutics. https://doi.org/10.1111/1755-5922.12435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.